Associated Banc Corp Has $9.13 Million Holdings in Stryker Corporation $SYK

Associated Banc Corp raised its holdings in Stryker Corporation (NYSE:SYK) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,088 shares of the medical technology company’s stock after acquiring an additional 826 shares during the period. Associated Banc Corp’s holdings in Stryker were worth $9,134,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of SYK. Nuveen LLC acquired a new position in shares of Stryker in the 1st quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Stryker by 66.7% in the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after buying an additional 549,643 shares during the period. ABN AMRO Bank N.V. bought a new stake in shares of Stryker during the second quarter worth $191,047,000. Finally, Vanguard Group Inc. raised its holdings in shares of Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after acquiring an additional 440,607 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $370.38 on Tuesday. The company has a market cap of $141.64 billion, a PE ratio of 49.06, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The firm has a 50-day moving average of $369.24 and a 200-day moving average of $380.59. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period last year, the business posted $2.87 EPS. Stryker’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Analysts Set New Price Targets

SYK has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. BTIG Research reaffirmed a “buy” rating and set a $410.00 price objective on shares of Stryker in a research report on Friday, November 14th. Redburn Partners set a $420.00 price objective on Stryker in a report on Thursday, September 18th. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 price target on shares of Stryker in a research note on Friday, November 14th. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Insider Activity

In other news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 522,118 shares of company stock valued at $185,381,932 over the last three months. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.